A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT05918692
Trial Phases:	Phase I	Protocol IDs:	COVALENT-103 (primary) NCI-2023-06835
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Biomea Fusion Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05918692

Summary

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral
FLT3 inhibitor, in adult patients with acute leukemia.

Objectives

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral
covalent FLT3 inhibitor, in adult patients with acute myeloid leukemia (AML), acute
lymphocytic leukemia (ALL) and Acute Mixed-Phenotype Leukemia (MPAL) who may or may not
be on Antifungals.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.